IOVA Q1 2025 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M+6798.5% YoY

Gross Profit

-$417,000-0.8% margin

Operating Income

-$121M-245.8% margin

Net Income

-$116M-235.5% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

-33.1%

Cash Flow

Operating Cash Flow

-$104M

Free Cash Flow

-$110M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$967M

Total Liabilities

$199M

Stockholders' Equity

$768M

Cash & Equivalents

$172M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$715,000	+6798.5%
Gross Profit	-$417,000	-$7M	+93.6%
Operating Income	-$121M	-$118M	-3.0%
Net Income	-$116M	-$113M	-2.8%

Geographic Segments

UNITED STATES

$49M98%

Non-US

$804,0002%